{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:00:33Z","timestamp":1780290033738,"version":"3.54.0"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03594-6","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:34:20Z","timestamp":1772854460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paradigm shift: from pulmonary vasodilation to cardiopulmonary dual-track therapy\u2014a comprehensive review of pathophysiology and advances in pulmonary hypertension-associated right heart failure"],"prefix":"10.1186","volume":"27","author":[{"given":"Rongtao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiange","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"2","key":"3594_CR1","first-page":"243","volume":"38","author":"SJ Cassady","year":"2020","unstructured":"Cassady SJ, Ramani GV. Right heart failure in pulmonary hypertension. Cardiol Clin. 2020;38(2):243\u201355.","journal-title":"Cardiol Clin"},{"issue":"2","key":"3594_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1183\/09031936.00148310","volume":"38","author":"A Campo","year":"2011","unstructured":"Campo A, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J. 2011;38(2):359\u201367.","journal-title":"Eur Respir J"},{"issue":"2","key":"3594_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.chest.2018.10.040","volume":"155","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, et al. Trends in hospitalization and in-hospital mortality from VTE, 2007 to 2016 China. Chest. 2019;155(2):342\u201353.","journal-title":"Chest"},{"issue":"4","key":"3594_CR4","first-page":"533","volume":"40","author":"VM Moles","year":"2022","unstructured":"Moles VM, Grafton G. Pulmonary hypertension in heart failure with preserved ejection fraction. Cardiol Clin. 2022;40(4):533\u201340.","journal-title":"Cardiol Clin"},{"issue":"13","key":"3594_CR5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA.107.653584","volume":"117","author":"F Haddad","year":"2008","unstructured":"Haddad F, et al. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117(13):1717\u201331.","journal-title":"Circulation"},{"issue":"4","key":"3594_CR6","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/ehf2.13386","volume":"8","author":"A Schmei\u00dfer","year":"2021","unstructured":"Schmei\u00dfer A, et al. Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction. ESC Heart Fail. 2021;8(4):2968\u201381.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"3594_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12880-025-01650-z","volume":"25","author":"G Lv","year":"2025","unstructured":"Lv G, et al. Assessment of right ventricle-to-pulmonary artery coupling by three-dimensional echocardiography in pre-capillary pulmonary hypertension: comparison with tricuspid annular plane systolic excursion \/systolic pulmonary artery pressure ratio. BMC Med Imaging. 2025;25(1):108.","journal-title":"BMC Med Imaging"},{"issue":"4","key":"3594_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/ehjci\/jey120","volume":"20","author":"HG Hulshof","year":"2019","unstructured":"Hulshof HG, et al. Prognostic value of right ventricular longitudinal strain in patients with pulmonary hypertension: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2019;20(4):475\u201384.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"3594_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1378\/chest.15-0300","volume":"148","author":"HW Farber","year":"2015","unstructured":"Farber HW, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043\u201354.","journal-title":"Chest"},{"issue":"25 Suppl","key":"3594_CR10","doi-asserted-by":"publisher","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","volume":"62","author":"MD McGoon","year":"2013","unstructured":"McGoon MD, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25 Suppl):D51\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"3594_CR11","doi-asserted-by":"crossref","unstructured":"GBD 2021 Pulmonary Arterial Hypertension Collaborators. Global, regional, and national burden of pulmonary arterial hypertension, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Respir Med. 2025;13(1):69\u201379.","DOI":"10.3389\/fpubh.2025.1516365"},{"issue":"1","key":"3594_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1378\/chest.12-2417","volume":"144","author":"RJ Barst","year":"2013","unstructured":"Barst RJ, et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest. 2013;144(1):160\u20138.","journal-title":"Chest"},{"issue":"4","key":"3594_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/ejhf.3172","volume":"26","author":"M D'Alto","year":"2024","unstructured":"D\u2019Alto M, et al. Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension. Eur J Heart Fail. 2024;26(4):817\u201324.","journal-title":"Eur J Heart Fail"},{"key":"3594_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ajem.2022.05.030","volume":"58","author":"M Kostura","year":"2022","unstructured":"Kostura M, et al. Right heart failure: a narrative review for emergency clinicians. Am J Emerg Med. 2022;58:106\u201313.","journal-title":"Am J Emerg Med"},{"key":"3594_CR15","doi-asserted-by":"crossref","unstructured":"Humbert, M., et al., 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023;61(1).","DOI":"10.1183\/13993003.00879-2022"},{"issue":"4","key":"3594_CR16","doi-asserted-by":"publisher","first-page":"e060223213452","DOI":"10.2174\/1573403X19666230206115611","volume":"19","author":"HN Tun","year":"2023","unstructured":"Tun HN, et al. Acute right ventricular failure: pathophysiology, diagnostic approach with emphasis on the role of echocardiography. Curr Cardiol Rev. 2023;19(4):e060223213452.","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"3594_CR17","doi-asserted-by":"publisher","first-page":"e15721","DOI":"10.1111\/echo.15721","volume":"41","author":"M Day\u0131o\u011flu","year":"2024","unstructured":"Day\u0131o\u011flu M, et al. Performance of handheld ultrasound devices in diagnosis of pulmonary hypertension and right heart dysfunction in ICU patients. Echocardiography. 2024;41(1):e15721.","journal-title":"Echocardiography"},{"issue":"3","key":"3594_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40138-021-00229-6","volume":"9","author":"AN Malik","year":"2021","unstructured":"Malik AN, et al. The use of handheld ultrasound devices in emergency medicine. Curr Emerg Hosp Med Rep. 2021;9(3):73\u201381.","journal-title":"Curr Emerg Hosp Med Rep"},{"issue":"1","key":"3594_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/bph.14866","volume":"178","author":"K Tello","year":"2021","unstructured":"Tello K, et al. Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. Br J Pharmacol. 2021;178(1):90\u2013107.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"3594_CR20","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/ejhf.1862","volume":"22","author":"E Santiago-Vacas","year":"2020","unstructured":"Santiago-Vacas E, et al. Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors. Eur J Heart Fail. 2020;22(7):1214\u201325.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"3594_CR21","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cardfail.2023.04.009","volume":"29","author":"C Baratto","year":"2023","unstructured":"Baratto C, et al. Right heart adaptation to exercise in pulmonary hypertension: an invasive hemodynamic study. J Card Fail. 2023;29(9):1261\u201372.","journal-title":"J Card Fail"},{"issue":"12","key":"3594_CR22","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.202012-4317SO","volume":"203","author":"BA Maron","year":"2021","unstructured":"Maron BA, et al. Pulmonary arterial hypertension: diagnosis, treatment, and novel advances. Am J Respir Crit Care Med. 2021;203(12):1472\u201387.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3594_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1164\/rccm.202302-0327SO","volume":"208","author":"S Johnson","year":"2023","unstructured":"Johnson S, et al. Pulmonary hypertension: a contemporary review. Am J Respir Crit Care Med. 2023;208(5):528\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"3594_CR24","doi-asserted-by":"crossref","unstructured":"Otani N, et al. Recent advances in the treatment of pulmonary arterial hypertension. Pharmaceuticals (Basel), 2022;15(10).","DOI":"10.3390\/ph15101277"},{"issue":"5","key":"3594_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/10742484211006531","volume":"26","author":"S Mandras","year":"2021","unstructured":"Mandras S, et al. Combination therapy in pulmonary arterial hypertension-targeting the nitric oxide and prostacyclin pathways. J Cardiovasc Pharmacol Ther. 2021;26(5):453\u201362.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3 Suppl","key":"3594_CR26","first-page":"S42","volume":"27","author":"S Gale","year":"2021","unstructured":"Gale S. The evolving treatment landscape of pulmonary arterial hypertension. Am J Manag Care. 2021;27(3 Suppl):S42-s52.","journal-title":"Am J Manag Care"},{"key":"3594_CR27","doi-asserted-by":"publisher","unstructured":"Truong R, Davis S, Rosario N, Wollen J, Johnson C, Wang Y, Wang EM. Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment. Ann Pharmacother. 2026;60:163-74. https:\/\/doi.org\/10.1177\/10600280251358959.","DOI":"10.1177\/10600280251358959"},{"issue":"22","key":"3594_CR28","doi-asserted-by":"publisher","first-page":"e018349","DOI":"10.1161\/JAHA.120.018349","volume":"9","author":"EL Brittain","year":"2020","unstructured":"Brittain EL, et al. Mechanistic phase II clinical trial of metformin in pulmonary arterial hypertension. J Am Heart Assoc. 2020;9(22):e018349.","journal-title":"J Am Heart Assoc"},{"key":"3594_CR29","doi-asserted-by":"publisher","unstructured":"Zhang Y, Li X, Li S, Zhou Y, Zhang T, Sun L. Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25158427.","DOI":"10.3390\/ijms25158427"},{"key":"3594_CR30","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-S\u00e1nchez J, Harlow L, Church C, Gaine S, Knightbridge E, Bunclark K, Gor D, Bedding A, Morrell N, Corris P, Toshner M. Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulm Circ. 2018;8:2045893217735820. https:\/\/doi.org\/10.1177\/2045893217735820.","DOI":"10.1177\/2045893217735820"},{"key":"3594_CR31","doi-asserted-by":"publisher","unstructured":"Brewer JM, Maybauer MO. The ProtekDuo Cannula: A Comprehensive Review of Efficacy and Clinical Applications in Right Ventricular Failure. J Clin Med. 2024;13(14). https:\/\/doi.org\/10.3390\/jcm13144077.","DOI":"10.3390\/jcm13144077"},{"issue":"1","key":"3594_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/aor.14461","volume":"47","author":"JJ Han","year":"2023","unstructured":"Han JJ. Impella RP flex with SmartAssist receives FDA pre-market approval. Artif Organs. 2023;47(1):10\u20131.","journal-title":"Artif Organs"},{"key":"3594_CR33","doi-asserted-by":"publisher","unstructured":"Kawashima M, et al. Extended Use of Central Veno-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Pulmonary Arterial Hypertension. Eur J Cardiothorac Surg. 2025;67(8):23. https:\/\/doi.org\/10.1093\/ejcts\/ezaf256.","DOI":"10.1093\/ejcts\/ezaf256"},{"issue":"4","key":"3594_CR34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S2213-2600(24)00425-9","volume":"13","author":"FF Rahaghi","year":"2025","unstructured":"Rahaghi FF, et al. Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients. Lancet Respir Med. 2025;13(4):364\u201370.","journal-title":"Lancet Respir Med"},{"key":"3594_CR35","doi-asserted-by":"publisher","unstructured":"Jin Q, et al. Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs. Pharmaceutics. 2023;15(6):12. https:\/\/doi.org\/10.3390\/pharmaceutics1506157.","DOI":"10.3390\/pharmaceutics1506157"},{"issue":"1","key":"3594_CR36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13054-016-1440-0","volume":"20","author":"MR Pinsky","year":"2016","unstructured":"Pinsky MR. The right ventricle: interaction with the pulmonary circulation. Crit Care. 2016;20(1):266.","journal-title":"Crit Care"},{"issue":"25 Suppl","key":"3594_CR37","doi-asserted-by":"publisher","first-page":"D22","DOI":"10.1016\/j.jacc.2013.10.027","volume":"62","author":"A Vonk-Noordegraaf","year":"2013","unstructured":"Vonk-Noordegraaf A, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013;62(25 Suppl):D22-33.","journal-title":"J Am Coll Cardiol"},{"key":"3594_CR38","doi-asserted-by":"crossref","unstructured":"Topy\u0142a-Putowska W, et al. Tricuspid Regurgitation Velocity\/Tricuspid Annular Plane Systolic Excursion (TRV\/TAPSE) ratio as a novel indicator of disease severity and prognosis in patients with precapillary pulmonary hypertension. Diseases, 2023;11(3)","DOI":"10.3390\/diseases11030117"},{"issue":"4","key":"3594_CR39","first-page":"272","volume":"10","author":"MC Todaro","year":"2020","unstructured":"Todaro MC, et al. Echocardiographic evaluation of right ventricular-arterial coupling in pulmonary hypertension. Am J Cardiovasc Dis. 2020;10(4):272\u201383.","journal-title":"Am J Cardiovasc Dis"},{"issue":"2","key":"3594_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/ehjci\/jeaa285","volume":"22","author":"A Schmeisser","year":"2021","unstructured":"Schmeisser A, et al. Pressure-volume loop validation of TAPSE\/PASP for right ventricular arterial coupling in heart failure with pulmonary hypertension. Eur Heart J Cardiovasc Imaging. 2021;22(2):168\u201376.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"3594_CR41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.31083\/j.rcm2412366","volume":"24","author":"H Li","year":"2023","unstructured":"Li H, et al. Assessment of right ventricular-arterial coupling by echocardiography in patients with right ventricular pressure and volume overload. Rev Cardiovasc Med. 2023;24(12):366.","journal-title":"Rev Cardiovasc Med"},{"issue":"11","key":"3594_CR42","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.echo.2023.06.014","volume":"36","author":"M Gavazzoni","year":"2023","unstructured":"Gavazzoni M, et al. Clinical value of a novel three-dimensional echocardiography-derived index of right ventricle-pulmonary artery coupling in tricuspid regurgitation. J Am Soc Echocardiogr. 2023;36(11):1154-1166.e3.","journal-title":"J Am Soc Echocardiogr"},{"key":"3594_CR43","doi-asserted-by":"crossref","unstructured":"Kazimierczyk R, et al. Echocardiographic assessment of right ventricular-arterial coupling in predicting prognosis of pulmonary arterial hypertension patients. J Clin Med. 2021;10(13):21.","DOI":"10.3390\/jcm10132995"},{"key":"3594_CR44","doi-asserted-by":"crossref","unstructured":"Leopold JA, Maron BA. Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension. Int J Mol Sci. 2016;17(5):12-13.","DOI":"10.3390\/ijms17050761"},{"key":"3594_CR45","doi-asserted-by":"crossref","unstructured":"Gomes MT, et al. Signal transduction during metabolic and inflammatory reprogramming in pulmonary vascular remodeling. Int J Mol Sci. 2022;23(5):5-7.","DOI":"10.3390\/ijms23052410"},{"key":"3594_CR46","doi-asserted-by":"publisher","first-page":"957524","DOI":"10.3389\/fcvm.2022.957524","volume":"9","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang L, Zhang W. Metabolic reprogramming: a novel metabolic model for pulmonary hypertension. Front Cardiovasc Med. 2022;9:957524.","journal-title":"Front Cardiovasc Med"},{"key":"3594_CR47","doi-asserted-by":"publisher","first-page":"667446","DOI":"10.3389\/fcvm.2021.667446","volume":"8","author":"R Mprah","year":"2021","unstructured":"Mprah R, et al. Glutaminolysis: a driver of vascular and cardiac remodeling in pulmonary arterial hypertension. Front Cardiovasc Med. 2021;8:667446.","journal-title":"Front Cardiovasc Med"},{"key":"3594_CR48","doi-asserted-by":"crossref","unstructured":"Riou M, et al. Targeting mitochondrial metabolic dysfunction in pulmonary hypertension: toward new therapeutic approaches? Int J Mol Sci, 2023;24(11)","DOI":"10.3390\/ijms24119572"},{"key":"3594_CR49","doi-asserted-by":"publisher","first-page":"117954682412747","DOI":"10.1177\/11795468241274744","volume":"18","author":"M Namazi","year":"2024","unstructured":"Namazi M, et al. Pulmonary hypertension and right ventricle: a pathophysiological insight. Clin Med Insights Cardiol. 2024;18:11795468241274744.","journal-title":"Clin Med Insights Cardiol"},{"key":"3594_CR50","doi-asserted-by":"publisher","first-page":"1105565","DOI":"10.3389\/fcell.2023.1105565","volume":"11","author":"NM Breault","year":"2023","unstructured":"Breault NM, et al. Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension. Front Cell Dev Biol. 2023;11:1105565.","journal-title":"Front Cell Dev Biol"},{"key":"3594_CR51","doi-asserted-by":"crossref","unstructured":"Hu Y, et al. Perivascular Inflammation in Pulmonary Arterial Hypertension. Cells. 2020;9(11):3-6.","DOI":"10.3390\/cells9112338"},{"key":"3594_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-3-030-63046-1_19","volume":"1303","author":"T Klouda","year":"2021","unstructured":"Klouda T, Yuan K. Inflammation in pulmonary arterial hypertension. Adv Exp Med Biol. 2021;1303:351\u201372.","journal-title":"Adv Exp Med Biol"},{"key":"3594_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-3-030-63046-1_15","volume":"1303","author":"S Liang","year":"2021","unstructured":"Liang S, et al. Cytokines, chemokines, and inflammation in pulmonary arterial hypertension. Adv Exp Med Biol. 2021;1303:275\u2013303.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"3594_CR54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1164\/rccm.202203-0490OC","volume":"207","author":"DM Moutsoglou","year":"2023","unstructured":"Moutsoglou DM, et al. Pulmonary arterial hypertension patients have a proinflammatory gut microbiome and altered circulating microbial metabolites. Am J Respir Crit Care Med. 2023;207(6):740\u201356.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3594_CR55","doi-asserted-by":"publisher","first-page":"oeac021","DOI":"10.1093\/ehjopen\/oeac021","volume":"2","author":"Y Yang","year":"2022","unstructured":"Yang Y, et al. High-circulating gut microbiota-dependent metabolite trimethylamine N-oxide is associated with poor prognosis in pulmonary arterial hypertension. Eur Heart J Open. 2022;2(5):oeac021.","journal-title":"Eur Heart J Open"},{"issue":"1","key":"3594_CR56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12890-024-03008-7","volume":"24","author":"X Li","year":"2024","unstructured":"Li X, et al. Causal impact of gut microbiota and associated metabolites on pulmonary arterial hypertension: a bidirectional Mendelian randomization study. BMC Pulm Med. 2024;24(1):185.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"3594_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21037\/atm-24-54","volume":"12","author":"SE Lemay","year":"2024","unstructured":"Lemay SE, et al. A HIF-2\u03b1-dependent KMT2E-AS1\/KMT2E axis orchestrates endothelial epigenetic and metabolic dysfunction in pulmonary hypertension. Ann Transl Med. 2024;12(3):55.","journal-title":"Ann Transl Med"},{"issue":"2","key":"3594_CR58","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s44319-023-00054-w","volume":"25","author":"H Kim","year":"2024","unstructured":"Kim H, et al. Pericytes contribute to pulmonary vascular remodeling via HIF2\u03b1 signaling. EMBO Rep. 2024;25(2):616\u201345.","journal-title":"EMBO Rep"},{"key":"3594_CR59","doi-asserted-by":"crossref","unstructured":"Ranchoux B, et al. DNA damage and pulmonary hypertension. Int J Mol Sci. 2016;17(6):2-8.","DOI":"10.3390\/ijms17060990"},{"issue":"12","key":"3594_CR60","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/ars.2020.8169","volume":"34","author":"A Gorelova","year":"2021","unstructured":"Gorelova A, Berman M, Al Ghouleh I. Endothelial-to-mesenchymal transition in pulmonary arterial hypertension. Antioxid Redox Signal. 2021;34(12):891\u2013914.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"3594_CR61","first-page":"102","volume":"48","author":"L Xiao","year":"2019","unstructured":"Xiao L, Tong X. [Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019;48(1):102\u201310.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"3594_CR62","doi-asserted-by":"crossref","unstructured":"Kazmirczak F, et al. Ferroptosis integrates mitochondrial derangements and pathological inflammation to promote pulmonary hypertension. bioRxiv 2024.","DOI":"10.1101\/2023.01.19.524721"},{"issue":"2","key":"3594_CR63","doi-asserted-by":"publisher","first-page":"L429","DOI":"10.1152\/ajplung.00555.2018","volume":"318","author":"AR Hemnes","year":"2020","unstructured":"Hemnes AR, et al. BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes. Am J Physiol Lung Cell Mol Physiol. 2020;318(2):L429-l441.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3594_CR64","doi-asserted-by":"crossref","unstructured":"Kocken, J.M.M. and P.A. da Costa Martins, Epigenetic regulation of pulmonary arterial hypertension-induced vascular and right ventricular remodeling: new opportunities? Int J Mol Sci, 2020;21(23)","DOI":"10.3390\/ijms21238901"},{"issue":"2","key":"3594_CR65","first-page":"235","volume":"12","author":"M Okni\u0144ska","year":"2024","unstructured":"Okni\u0144ska M, et al. Role of oxygen starvation in right ventricular decompensation and failure in pulmonary arterial hypertension. JACC: Heart Failure. 2024;12(2):235\u201347.","journal-title":"JACC: Heart Failure"},{"key":"3594_CR66","doi-asserted-by":"publisher","first-page":"102797","DOI":"10.1016\/j.redox.2023.102797","volume":"64","author":"MD Pokharel","year":"2023","unstructured":"Pokharel MD, et al. Metabolic reprogramming, oxidative stress, and pulmonary hypertension. Redox Biol. 2023;64:102797.","journal-title":"Redox Biol"},{"issue":"1","key":"3594_CR67","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCRESAHA.113.301129","volume":"115","author":"JJ Ryan","year":"2014","unstructured":"Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014;115(1):176\u201388.","journal-title":"Circ Res"},{"key":"3594_CR68","doi-asserted-by":"crossref","unstructured":"Vanderpool RR, et al. Reversal of right ventricular hypertrophy and dysfunction by prostacyclin in a rat model of severe pulmonary arterial hypertension. Int J Mol Sci, 2022;23(10)","DOI":"10.3390\/ijms23105426"},{"key":"3594_CR69","doi-asserted-by":"crossref","unstructured":"Liang S, et al. Mitochondrial metabolism, redox, and calcium homeostasis in pulmonary arterial hypertension. Biomedicines. 2022;10(2):7-12.","DOI":"10.3390\/biomedicines10020341"},{"issue":"2","key":"3594_CR70","doi-asserted-by":"publisher","first-page":"101635","DOI":"10.1016\/j.disamonth.2023.101635","volume":"70","author":"SG Pawar","year":"2024","unstructured":"Pawar SG, et al. The association of Pulmonary Hypertension and right ventricular systolic function - updates in diagnosis and treatment. Dis Mon. 2024;70(2):101635.","journal-title":"Dis Mon"},{"issue":"1","key":"3594_CR71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12931-025-03163-3","volume":"26","author":"TY Peng","year":"2025","unstructured":"Peng TY, et al. The role of lactate metabolism and lactylation in pulmonary arterial hypertension. Respir Res. 2025;26(1):99.","journal-title":"Respir Res"},{"issue":"1","key":"3594_CR72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1161\/CIRCRESAHA.122.321554","volume":"132","author":"I Cuthbertson","year":"2023","unstructured":"Cuthbertson I, Morrell NW, Caruso P. BMPR2 mutation and metabolic reprogramming in pulmonary arterial hypertension. Circ Res. 2023;132(1):109\u201326.","journal-title":"Circ Res"},{"issue":"3","key":"3594_CR73","doi-asserted-by":"publisher","first-page":"L355","DOI":"10.1152\/ajplung.00039.2022","volume":"323","author":"MH Lee","year":"2022","unstructured":"Lee MH, et al. Contribution of fatty acid oxidation to the pathogenesis of pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2022;323(3):L355-l371.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"3594_CR74","doi-asserted-by":"publisher","first-page":"L252","DOI":"10.1152\/ajplung.00199.2023","volume":"326","author":"N Philip","year":"2024","unstructured":"Philip N, et al. Fatty acid metabolism promotes TRPV4 activity in lung microvascular endothelial cells in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2024;326(3):L252-l265.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3594_CR75","doi-asserted-by":"crossref","unstructured":"Legchenko E, et al. PPAR\u03b3 agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med, 2018;10(438)","DOI":"10.1126\/scitranslmed.aao0303"},{"issue":"12","key":"3594_CR76","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/ehjci\/jev136","volume":"17","author":"H Ohira","year":"2016","unstructured":"Ohira H, et al. Shifts in myocardial fatty acid and glucose metabolism in pulmonary arterial hypertension: a potential mechanism for a maladaptive right ventricular response. Eur Heart J Cardiovasc Imaging. 2016;17(12):1424\u201331.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"3594_CR77","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.freeradbiomed.2020.12.452","volume":"170","author":"D Wu","year":"2021","unstructured":"Wu D, et al. Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer. Free Radic Biol Med. 2021;170:150\u201378.","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"3594_CR78","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1161\/HYPERTENSIONAHA.124.22822","volume":"81","author":"D Wu","year":"2024","unstructured":"Wu D, et al. Novel Drp1 GTPase inhibitor, Drpitor1a: efficacy in pulmonary hypertension. Hypertension. 2024;81(10):2189\u2013201.","journal-title":"Hypertension"},{"issue":"23","key":"3594_CR79","doi-asserted-by":"publisher","first-page":"23684","DOI":"10.18632\/aging.103892","volume":"12","author":"B Zhuan","year":"2020","unstructured":"Zhuan B, et al. Hypoxia induces pulmonary artery smooth muscle dysfunction through mitochondrial fragmentation-mediated endoplasmic reticulum stress. Aging (Albany NY). 2020;12(23):23684\u201397.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"3594_CR80","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00109-017-1522-8","volume":"95","author":"L Tian","year":"2017","unstructured":"Tian L, et al. Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension. J Mol Med (Berl). 2017;95(4):381\u201393.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"3594_CR81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12931-018-0776-1","volume":"19","author":"O Rafikova","year":"2018","unstructured":"Rafikova O, et al. Recurrent inhibition of mitochondrial complex III induces chronic pulmonary vasoconstriction and glycolytic switch in the rat lung. Respir Res. 2018;19(1):69.","journal-title":"Respir Res"},{"key":"3594_CR82","doi-asserted-by":"crossref","unstructured":"Niihori M, et al. Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension. J Exp Med. 2024;221(11):26.","DOI":"10.1084\/jem.20231568"},{"issue":"1","key":"3594_CR83","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12931-025-03099-8","volume":"26","author":"X Zhang","year":"2025","unstructured":"Zhang X, et al. Dysfunction in mitochondrial electron transport chain drives the pathogenesis of pulmonary arterial hypertension: insights from a multi-omics investigation. Respir Res. 2025;26(1):29.","journal-title":"Respir Res"},{"key":"3594_CR84","doi-asserted-by":"crossref","unstructured":"Xu D, et al. Oxidative stress and antioxidative therapy in pulmonary arterial hypertension. Molecules. 2022;27(12):35.","DOI":"10.3390\/molecules27123724"},{"issue":"6","key":"3594_CR85","doi-asserted-by":"publisher","first-page":"e13048","DOI":"10.1111\/cpr.13048","volume":"54","author":"W Feng","year":"2021","unstructured":"Feng W, et al. ERK\/Drp1-dependent mitochondrial fission contributes to HMGB1-induced autophagy in pulmonary arterial hypertension. Cell Prolif. 2021;54(6):e13048.","journal-title":"Cell Prolif"},{"issue":"1","key":"3594_CR86","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12964-023-01216-y","volume":"21","author":"Y Xiong","year":"2023","unstructured":"Xiong Y, et al. Decreased MFN2 activates the cGAS-STING pathway in diabetic myocardial ischaemia-reperfusion by triggering the release of mitochondrial DNA. Cell Commun Signal. 2023;21(1):192.","journal-title":"Cell Commun Signal"},{"key":"3594_CR87","doi-asserted-by":"crossref","unstructured":"Shah AJ, et al. New drugs and therapies in pulmonary arterial hypertension. Int J Mol Sci. 2023;24(6):3.","DOI":"10.3390\/ijms24065850"},{"issue":"3","key":"3594_CR88","doi-asserted-by":"publisher","first-page":"25781","DOI":"10.31083\/RCM25781","volume":"26","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang Y, Zhang W. Dysregulation of mitochondrial in pulmonary hypertension-related right ventricular remodeling: pathophysiological features and targeting drugs. Rev Cardiovasc Med. 2025;26(3):25781.","journal-title":"Rev Cardiovasc Med"},{"issue":"7\u20139","key":"3594_CR89","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/ars.2024.0557","volume":"42","author":"S Farha","year":"2025","unstructured":"Farha S, et al. Alterations in mitochondrial function in pulmonary vascular diseases. Antioxid Redox Signal. 2025;42(7\u20139):361\u201377.","journal-title":"Antioxid Redox Signal"},{"key":"3594_CR90","doi-asserted-by":"publisher","first-page":"959209","DOI":"10.3389\/fimmu.2022.959209","volume":"13","author":"SF Liu","year":"2022","unstructured":"Liu SF, et al. Pulmonary hypertension: linking inflammation and pulmonary arterial stiffening. Front Immunol. 2022;13:959209.","journal-title":"Front Immunol"},{"issue":"7","key":"3594_CR91","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.hlc.2022.02.007","volume":"31","author":"S Ni","year":"2022","unstructured":"Ni S, et al. Immune cells in pulmonary arterial hypertension. Heart Lung Circ. 2022;31(7):934\u201343.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"3594_CR92","doi-asserted-by":"publisher","first-page":"331","DOI":"10.7150\/ijbs.66472","volume":"18","author":"PL Chi","year":"2022","unstructured":"Chi PL, et al. MMP-10 from M1 macrophages promotes pulmonary vascular remodeling and pulmonary arterial hypertension. Int J Biol Sci. 2022;18(1):331\u201348.","journal-title":"Int J Biol Sci"},{"key":"3594_CR93","doi-asserted-by":"publisher","first-page":"102094","DOI":"10.1016\/j.pupt.2021.102094","volume":"72","author":"Z Han","year":"2022","unstructured":"Han Z, et al. The roles of immune system and autoimmunity in pulmonary arterial hypertension: a review. Pulm Pharmacol Ther. 2022;72:102094.","journal-title":"Pulm Pharmacol Ther"},{"issue":"37","key":"3594_CR94","doi-asserted-by":"publisher","first-page":"e39670","DOI":"10.1097\/MD.0000000000039670","volume":"103","author":"D Du","year":"2024","unstructured":"Du D, et al. Causal relationship between immune cells and pulmonary arterial hypertension: Mendelian randomization analysis. Medicine (Baltimore). 2024;103(37):e39670.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"3594_CR95","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.14336\/AD.2020.0111","volume":"11","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, et al. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review. Aging Dis. 2020;11(6):1623\u201339.","journal-title":"Aging Dis"},{"issue":"1","key":"3594_CR96","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","volume":"115","author":"M Rabinovitch","year":"2014","unstructured":"Rabinovitch M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115(1):165\u201375.","journal-title":"Circ Res"},{"key":"3594_CR97","doi-asserted-by":"publisher","first-page":"929752","DOI":"10.3389\/fmicb.2022.929752","volume":"13","author":"L Huang","year":"2022","unstructured":"Huang L, et al. The role of gut and airway microbiota in pulmonary arterial hypertension. Front Microbiol. 2022;13:929752.","journal-title":"Front Microbiol"},{"key":"3594_CR98","doi-asserted-by":"crossref","unstructured":"Suswa\u0142 K, et al. Gut-lung axis in focus: deciphering the impact of gut microbiota on pulmonary arterial hypertension. J Pers Med. 2023;14(1);36.","DOI":"10.3390\/jpm14010008"},{"key":"3594_CR99","doi-asserted-by":"crossref","unstructured":"Chen YH, et al. The role and mechanism of gut microbiota in pulmonary arterial hypertension. Nutrients. 2022;14(20);14.","DOI":"10.3390\/nu14204278"},{"key":"3594_CR100","doi-asserted-by":"publisher","first-page":"102115","DOI":"10.1016\/j.redox.2021.102115","volume":"46","author":"S Jiang","year":"2021","unstructured":"Jiang S, et al. Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II-induced hypertension. Redox Biol. 2021;46:102115.","journal-title":"Redox Biol"},{"issue":"5","key":"3594_CR101","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/ATVBAHA.121.316236","volume":"42","author":"SD Oliveira","year":"2022","unstructured":"Oliveira SD. Insights on the gut-mesentery-lung axis in pulmonary arterial hypertension: a poorly investigated crossroad. Arterioscler Thromb Vasc Biol. 2022;42(5):516\u201326.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"3594_CR102","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12931-021-01872-z","volume":"22","author":"N Li","year":"2021","unstructured":"Li N, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respir Res. 2021;22(1):274.","journal-title":"Respir Res"},{"issue":"1","key":"3594_CR103","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s10020-024-00975-9","volume":"30","author":"C Chen","year":"2024","unstructured":"Chen C, et al. PI3K p85\u03b1\/HIF-1\u03b1 accelerates the development of pulmonary arterial hypertension by regulating fatty acid uptake and mitophagy. Mol Med. 2024;30(1):208.","journal-title":"Mol Med"},{"key":"3594_CR104","doi-asserted-by":"publisher","first-page":"113544","DOI":"10.1016\/j.biopha.2022.113544","volume":"154","author":"M Okni\u0144ska","year":"2022","unstructured":"Okni\u0144ska M, et al. New potential treatment for cardiovascular disease through modulation of hemoglobin oxygen binding curve: Myo-inositol trispyrophosphate (ITPP), from cancer to cardiovascular disease. Biomed Pharmacother. 2022;154:113544.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3594_CR105","doi-asserted-by":"publisher","first-page":"e90427","DOI":"10.1172\/jci.insight.90427","volume":"2","author":"PI Chen","year":"2017","unstructured":"Chen PI, et al. Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI Insight. 2017;2(2):e90427.","journal-title":"JCI Insight"},{"issue":"11","key":"3594_CR106","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1161\/CIRCRESAHA.123.324138","volume":"135","author":"F Kazmirczak","year":"2024","unstructured":"Kazmirczak F, et al. Ferroptosis-mediated inflammation promotes pulmonary hypertension. Circ Res. 2024;135(11):1067\u201383.","journal-title":"Circ Res"},{"key":"3594_CR107","doi-asserted-by":"crossref","unstructured":"Han Y, et al. Role of long non-coding RNAs in pulmonary arterial hypertension. Cells. 2021;10(8);34-7.","DOI":"10.3390\/cells10081892"},{"key":"3594_CR108","doi-asserted-by":"crossref","unstructured":"Hsu CH, et al. miR-29a-3p\/THBS2 axis regulates PAH-Induced cardiac fibrosis. Int J Mol Sci. 2021;22(19);25.","DOI":"10.3390\/ijms221910574"},{"issue":"3","key":"3594_CR109","doi-asserted-by":"publisher","first-page":"L319","DOI":"10.1152\/ajplung.00110.2024","volume":"327","author":"TV Kudryashova","year":"2024","unstructured":"Kudryashova TV, et al. PAI-1 deficiency drives pulmonary vascular smooth muscle remodeling and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2024;327(3):L319-l326.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3594_CR110","doi-asserted-by":"crossref","unstructured":"Martin de Miguel I, et al. Novel molecular mechanisms involved in the medical treatment of pulmonary arterial hypertension. Int J Mol Sci 2023;24(4)","DOI":"10.3390\/ijms24044147"},{"issue":"7","key":"3594_CR111","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40265-024-02058-9","volume":"84","author":"C Kang","year":"2024","unstructured":"Kang C. Sotatercept: first approval. Drugs. 2024;84(7):857\u201362.","journal-title":"Drugs"},{"key":"3594_CR112","doi-asserted-by":"crossref","unstructured":"Madonna R, Biondi F, Perspectives on sotatercept in pulmonary arterial hypertension. J Clin Med, 2024;13(21)","DOI":"10.3390\/jcm13216463"},{"issue":"3","key":"3594_CR113","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/FJC.0000000000001665","volume":"85","author":"X Chen","year":"2025","unstructured":"Chen X, Xue B, Xu L. Efficacy and safety of treating pulmonary arterial hypertension with Imatinib: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2025;85(3):177\u201385.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"3594_CR114","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1164\/rccm.202504-0842LE","volume":"211","author":"Y Ding","year":"2025","unstructured":"Ding Y, et al. Imatinib: a promising therapeutic shining light on pulmonary arterial hypertension treatment. Am J Respir Crit Care Med. 2025;211(8):1531\u20132.","journal-title":"Am J Respir Crit Care Med"},{"key":"3594_CR115","doi-asserted-by":"crossref","unstructured":"Galkin A, et al. Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. Eur Respir J. 2022;60(6):12.","DOI":"10.1183\/13993003.02356-2021"},{"issue":"2","key":"3594_CR116","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1161\/HYPERTENSIONAHA.116.07353","volume":"68","author":"A Dean","year":"2016","unstructured":"Dean A, et al. Metformin reverses development of pulmonary hypertension via aromatase inhibition. Hypertension. 2016;68(2):446\u201354.","journal-title":"Hypertension"},{"key":"3594_CR117","doi-asserted-by":"crossref","unstructured":"Daubert MA, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(12):234-7.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004389"},{"issue":"1","key":"3594_CR118","doi-asserted-by":"publisher","first-page":"204589321773582","DOI":"10.1177\/2045893217735820","volume":"8","author":"J Hern\u00e1ndez-S\u00e1nchez","year":"2018","unstructured":"Hern\u00e1ndez-S\u00e1nchez J, et al. Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulm Circ. 2018;8(1):2045893217735820.","journal-title":"Pulm Circ"},{"issue":"3","key":"3594_CR119","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1164\/rccm.201809-1631LE","volume":"199","author":"CR Trankle","year":"2019","unstructured":"Trankle CR, et al. IL-1 blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single-arm, open-label, phase IB\/II pilot study. Am J Respir Crit Care Med. 2019;199(3):381\u20134.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3594_CR120","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1164\/rccm.201811-2192ED","volume":"199","author":"CJ Mullin","year":"2019","unstructured":"Mullin CJ, Kato GJ, Ventetuolo CE. Anakinra, what is thy bidding in pulmonary hypertension? Am J Respir Crit Care Med. 2019;199(3):267\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl_1","key":"3594_CR121","first-page":"A15288","volume":"138","author":"CR Trankle","year":"2018","unstructured":"Trankle CR, et al. Abstract 15288: Interleukin-1 blockade in patients with pulmonary arterial hypertension and right ventricular failure. Circulation. 2018;138(Suppl_1):A15288\u2013A15288.","journal-title":"Circulation"},{"issue":"1","key":"3594_CR122","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1038\/s41598-022-11435-x","volume":"12","author":"SR Joshi","year":"2022","unstructured":"Joshi SR, et al. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep. 2022;12(1):7803.","journal-title":"Sci Rep"},{"issue":"1","key":"3594_CR123","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12325-023-02684-x","volume":"41","author":"V McLaughlin","year":"2024","unstructured":"McLaughlin V, et al. Population health model predicting the long-term impact of sotatercept on morbidity and mortality in patients with Pulmonary Arterial Hypertension (PAH). Adv Ther. 2024;41(1):130\u201351.","journal-title":"Adv Ther"},{"key":"3594_CR124","doi-asserted-by":"crossref","unstructured":"Preston IR, et al. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J 2025;66(1)","DOI":"10.1183\/13993003.01435-2024"},{"key":"3594_CR125","doi-asserted-by":"crossref","unstructured":"Anand SC, et al. Sotatercept: a new era in pulmonary arterial hypertension. Cardiol Rev 2025.","DOI":"10.1097\/CRD.0000000000000837"},{"issue":"16","key":"3594_CR126","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478\u201390.","journal-title":"N Engl J Med"},{"key":"3594_CR127","doi-asserted-by":"crossref","unstructured":"Shalabi L, et al. Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Naunyn Schmiedebergs Arch Pharmacol, 2025","DOI":"10.1007\/s00210-025-04424-0"},{"key":"3594_CR128","doi-asserted-by":"publisher","unstructured":"Miranda AC, Cornelio CK, Tran BAC, Fernandez J. Sotatercept: A First-In-Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension. J Pharm Technol. 2025;41:134-43. https:\/\/doi.org\/10.1177\/87551225251317957.","DOI":"10.1177\/87551225251317957"},{"key":"3594_CR129","doi-asserted-by":"crossref","unstructured":"Humbert M, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J 2023;61(1)","DOI":"10.1183\/13993003.01347-2022"},{"key":"3594_CR130","doi-asserted-by":"crossref","unstructured":"Cracowski JL, Khouri C, Sotatercept in pulmonary arterial hypertension. Trends Pharmacol Sci 2025","DOI":"10.1016\/j.tips.2025.04.008"},{"issue":"1","key":"3594_CR131","doi-asserted-by":"publisher","first-page":"e12352","DOI":"10.1002\/pul2.12352","volume":"14","author":"H Gillies","year":"2024","unstructured":"Gillies H, et al. IMPAHCT: a randomized phase 2b\/3 study of inhaled imatinib for pulmonary arterial hypertension. Pulm Circ. 2024;14(1):e12352.","journal-title":"Pulm Circ"},{"issue":"6","key":"3594_CR132","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1164\/rccm.202410-1929OC","volume":"211","author":"AMK Rothman","year":"2025","unstructured":"Rothman AMK, et al. Positioning Imatinib for pulmonary arterial hypertension: a dose-finding phase 2 study. Am J Respir Crit Care Med. 2025;211(6):1018\u201327.","journal-title":"Am J Respir Crit Care Med"},{"key":"3594_CR133","doi-asserted-by":"publisher","first-page":"758763","DOI":"10.3389\/fphar.2021.758763","volume":"12","author":"Y Shi","year":"2021","unstructured":"Shi Y, et al. Combination therapy with Rapamycin and low dose Imatinib in pulmonary hypertension. Front Pharmacol. 2021;12:758763.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3594_CR134","doi-asserted-by":"publisher","first-page":"114154","DOI":"10.1016\/j.yexcr.2024.114154","volume":"441","author":"W Huang","year":"2024","unstructured":"Huang W, et al. A novel PDGFR inhibitor WQ-C-401 prevents pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension. Exp Cell Res. 2024;441(1):114154.","journal-title":"Exp Cell Res"},{"issue":"11","key":"3594_CR135","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1111\/bph.70006","volume":"182","author":"X Zeng","year":"2025","unstructured":"Zeng X, et al. Imatinib aggravates pressure-overload-induced right ventricle failure via JNK\/Runx2 pathway. Br J Pharmacol. 2025;182(11):2560\u201381.","journal-title":"Br J Pharmacol"},{"key":"3594_CR136","doi-asserted-by":"crossref","unstructured":"Pullamsetti SS, et al. Pharmacology and rationale for seralutinib in the treatment of pulmonary arterial hypertension. Int J Mol Sci. 2023;24(16);24-5.","DOI":"10.3390\/ijms241612653"},{"issue":"1","key":"3594_CR137","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4244\/AIJ-E-22-00001","volume":"8","author":"F Guo","year":"2022","unstructured":"Guo F, Jing ZC. Beyond medications: is pulmonary artery denervation the answer for pulmonary arterial hypertension? PADN for PAH. AsiaIntervention. 2022;8(1):14\u20135.","journal-title":"AsiaIntervention"},{"issue":"3","key":"3594_CR138","first-page":"381","volume":"12","author":"M Tannu","year":"2023","unstructured":"Tannu M, Krasuski RA. The evolution of pulmonary artery denervation for treatment of pulmonary arterial hypertension. Interv Cardiol Clin. 2023;12(3):381\u201391.","journal-title":"Interv Cardiol Clin"},{"issue":"23","key":"3594_CR139","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.jcin.2022.09.013","volume":"15","author":"H Zhang","year":"2022","unstructured":"Zhang H, et al. Pulmonary artery denervation for pulmonary arterial hypertension: a sham-controlled randomized PADN-CFDA trial. JACC Cardiovasc Interv. 2022;15(23):2412\u201323.","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"3594_CR140","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.jcin.2022.10.004","volume":"15","author":"JA Leopold","year":"2022","unstructured":"Leopold JA. Pulmonary artery denervation: a new therapeutic for pulmonary arterial hypertension? JACC Cardiovasc Interv. 2022;15(23):2424\u20136.","journal-title":"JACC Cardiovasc Interv"},{"issue":"8 Pt 2","key":"3594_CR141","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jchf.2023.05.016","volume":"11","author":"H Zhang","year":"2023","unstructured":"Zhang H, et al. 3-year outcome in patients with combined precapillary and postcapillary pulmonary hypertension: results from PADN-5 trial. JACC Heart Fail. 2023;11(8 Pt 2):1135\u201346.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"3594_CR142","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/ehf2.14842","volume":"11","author":"X Wu","year":"2024","unstructured":"Wu X, et al. Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta-analysis. ESC Heart Fail. 2024;11(5):2889\u2013900.","journal-title":"ESC Heart Fail"},{"issue":"8","key":"3594_CR143","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.healun.2023.03.015","volume":"42","author":"J Zhang","year":"2023","unstructured":"Zhang J, et al. Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: results from PADN-CFDA trial. J Heart Lung Transplant. 2023;42(8):1140\u201351.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"3594_CR144","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CRD.0000000000000299","volume":"29","author":"CW Kim","year":"2021","unstructured":"Kim CW, et al. Pulmonary artery denervation as an innovative treatment for pulmonary hypertension with and without heart failure. Cardiol Rev. 2021;29(2):89\u201395.","journal-title":"Cardiol Rev"},{"issue":"3","key":"3594_CR145","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5603\/CJ.a2020.0186","volume":"29","author":"Y Xie","year":"2022","unstructured":"Xie Y, et al. The progress of pulmonary artery denervation. Cardiol J. 2022;29(3):381\u20137.","journal-title":"Cardiol J"},{"issue":"1","key":"3594_CR146","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s40001-025-02776-0","volume":"30","author":"M Dong","year":"2025","unstructured":"Dong M, Song M, Liu J. Atrial septostomy in the management of pulmonary arterial hypertension: past, present, and future. Eur J Med Res. 2025;30(1):552.","journal-title":"Eur J Med Res"},{"key":"3594_CR147","doi-asserted-by":"crossref","unstructured":"St\u0105cel T, et al. Interventional and surgical treatments for pulmonary arterial hypertension. J Clin Med, 2021;10(15)","DOI":"10.3390\/jcm10153326"},{"issue":"1","key":"3594_CR148","doi-asserted-by":"publisher","first-page":"18287","DOI":"10.1038\/s41598-024-69002-5","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, et al. Animal models of pulmonary arterial hypertension associated with atrial septal defect. Sci Rep. 2024;14(1):18287.","journal-title":"Sci Rep"},{"key":"3594_CR149","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijcard.2022.12.002","volume":"373","author":"C Xing","year":"2023","unstructured":"Xing C, et al. Outcomes of atrial septostomy and effect on long-term survival in patients with idiopathic pulmonary arterial hypertension: a single-center cohort. Int J Cardiol. 2023;373:118\u201323.","journal-title":"Int J Cardiol"},{"issue":"9","key":"3594_CR150","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/eurheartj\/ehad822","volume":"45","author":"XM Li","year":"2024","unstructured":"Li XM, Zhu XJ, Jing ZC. Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure. Eur Heart J. 2024;45(9):738.","journal-title":"Eur Heart J"},{"key":"3594_CR151","doi-asserted-by":"publisher","first-page":"1577570","DOI":"10.3389\/fphar.2025.1577570","volume":"16","author":"A Chida-Nagai","year":"2025","unstructured":"Chida-Nagai A, et al. Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats. Front Pharmacol. 2025;16:1577570.","journal-title":"Front Pharmacol"},{"key":"3594_CR152","doi-asserted-by":"publisher","first-page":"116897","DOI":"10.1016\/j.bcp.2025.116897","volume":"236","author":"Y Meng","year":"2025","unstructured":"Meng Y, et al. xCT\/Slc7a11 promotes pulmonary arterial hypertension by disrupting AMPK\u03b1 suppression of mTOR activation. Biochem Pharmacol. 2025;236:116897.","journal-title":"Biochem Pharmacol"},{"key":"3594_CR153","doi-asserted-by":"publisher","first-page":"1276422","DOI":"10.3389\/fmed.2023.1276422","volume":"10","author":"M Talati","year":"2023","unstructured":"Talati M, et al. A potential adverse role for leptin and cardiac leptin receptor in the right ventricle in pulmonary arterial hypertension: effect of metformin is BMPR2 mutation-specific. Front Med. 2023;10:1276422.","journal-title":"Front Med"},{"key":"3594_CR154","doi-asserted-by":"publisher","first-page":"965613","DOI":"10.3389\/fphar.2022.965613","volume":"13","author":"P Remiszewski","year":"2022","unstructured":"Remiszewski P, et al. Effects of the peripheral CB(1) receptor antagonist JD5037 in mono- and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension. Front Pharmacol. 2022;13:965613.","journal-title":"Front Pharmacol"},{"issue":"6","key":"3594_CR155","doi-asserted-by":"publisher","first-page":"e70026","DOI":"10.1111\/acel.70026","volume":"24","author":"W Mitchell","year":"2025","unstructured":"Mitchell W, et al. The mitochondria-targeted peptide therapeutic elamipretide improves cardiac and skeletal muscle function during aging without detectable changes in tissue epigenetic or transcriptomic age. Aging Cell. 2025;24(6):e70026.","journal-title":"Aging Cell"},{"key":"3594_CR156","first-page":"100571","volume":"19","author":"G Guglielmi","year":"2025","unstructured":"Guglielmi G, Dimopoulos K, Wort SJ. New therapies in pulmonary arterial hypertension: recent insights. Int J Cardiol Congenit Heart Dis. 2025;19:100571.","journal-title":"Int J Cardiol Congenit Heart Dis"},{"issue":"1","key":"3594_CR157","doi-asserted-by":"publisher","first-page":"e009290","DOI":"10.1161\/CIRCHEARTFAILURE.121.009290","volume":"15","author":"DL Mann","year":"2022","unstructured":"Mann DL. Targeting inflammation in pulmonary artery hypertension: is it time to forget about the lungs? Circ Heart Fail. 2022;15(1):e009290.","journal-title":"Circ Heart Fail"},{"issue":"3","key":"3594_CR158","doi-asserted-by":"publisher","first-page":"e12101","DOI":"10.1002\/pul2.12101","volume":"12","author":"E Mavrogiannis","year":"2022","unstructured":"Mavrogiannis E, et al. Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation. Pulm Circ. 2022;12(3):e12101.","journal-title":"Pulm Circ"},{"issue":"3","key":"3594_CR159","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1096\/fj.201801659R","volume":"33","author":"PB Poble","year":"2019","unstructured":"Poble PB, et al. Therapeutic effect of pirfenidone in the sugen\/hypoxia rat model of severe pulmonary hypertension. Faseb j. 2019;33(3):3670\u20139.","journal-title":"Faseb j"},{"issue":"6","key":"3594_CR160","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1164\/rccm.201801-0195LE","volume":"198","author":"MJ Richter","year":"2018","unstructured":"Richter MJ, et al. Nintedanib in severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2018;198(6):808\u201310.","journal-title":"Am J Respir Crit Care Med"},{"key":"3594_CR161","doi-asserted-by":"publisher","first-page":"176547","DOI":"10.1016\/j.ejphar.2024.176547","volume":"972","author":"I Roger","year":"2024","unstructured":"Roger I, et al. Pirfenidone and nintedanib attenuates pulmonary artery endothelial and smooth muscle cells transformations induced by IL-11. Eur J Pharmacol. 2024;972:176547.","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"3594_CR162","doi-asserted-by":"publisher","first-page":"308","DOI":"10.31083\/j.rcm2309308","volume":"23","author":"M Salem","year":"2022","unstructured":"Salem M, Al-Saffar F, Hall S. Management of pulmonary hypertension in patients on left ventricular assist device support. Rev Cardiovasc Med. 2022;23(9):308.","journal-title":"Rev Cardiovasc Med"},{"key":"3594_CR163","doi-asserted-by":"crossref","unstructured":"Botti G, et al. Impella RP for patients with acute right ventricular failure and cardiogenic shock: a subanalysis from the IMP-IT registry. J Pers Med, 2022;12(9)","DOI":"10.3390\/jpm12091481"},{"issue":"6","key":"3594_CR164","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s12265-021-10131-x","volume":"14","author":"J Josiassen","year":"2021","unstructured":"Josiassen J, et al. Impella RP versus pharmacologic vasoactive treatment in profound cardiogenic shock due to right ventricular failure. J Cardiovasc Transl Res. 2021;14(6):1021\u20139.","journal-title":"J Cardiovasc Transl Res"},{"issue":"4","key":"3594_CR165","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2217\/fca-2021-0075","volume":"18","author":"A Montisci","year":"2022","unstructured":"Montisci A, et al. Comprehensive evaluation of Impella RP(\u00ae) in right ventricular failure. Future Cardiol. 2022;18(4):285\u201398.","journal-title":"Future Cardiol"},{"issue":"5","key":"3594_CR166","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/02676591221090607","volume":"38","author":"MO Maybauer","year":"2023","unstructured":"Maybauer MO, et al. The novel ProtekDuo ventricular assist device: configurations, technical aspects, and present evidence. Perfusion. 2023;38(5):887\u201393.","journal-title":"Perfusion"},{"issue":"7","key":"3594_CR167","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/aor.14525","volume":"47","author":"A Alam","year":"2023","unstructured":"Alam A, et al. Safety and efficacy of ProtekDuo right ventricular assist device: a systemic review. Artif Organs. 2023;47(7):1094\u2013103.","journal-title":"Artif Organs"},{"issue":"1_suppl","key":"3594_CR168","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/02676591221149859","volume":"38","author":"JM Brewer","year":"2023","unstructured":"Brewer JM, et al. The ProtekDuo dual-lumen cannula for temporary acute mechanical circulatory support in right heart failure: a systematic review. Perfusion. 2023;38(1_suppl):59\u201367.","journal-title":"Perfusion"},{"issue":"1","key":"3594_CR169","first-page":"129","volume":"40","author":"MM Budev","year":"2022","unstructured":"Budev MM, Yun JJ. Advanced circulatory support and lung transplantation in pulmonary hypertension. Cardiol Clin. 2022;40(1):129\u201338.","journal-title":"Cardiol Clin"},{"issue":"3","key":"3594_CR170","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/a-2590-2620","volume":"150","author":"S Kruszona","year":"2025","unstructured":"Kruszona S, et al. Pulmonary hypertension and lung transplantation. Zentralbl Chir. 2025;150(3):273\u201385.","journal-title":"Zentralbl Chir"},{"key":"3594_CR171","first-page":"100848","volume":"80","author":"J Khoury","year":"2021","unstructured":"Khoury J, et al. Veno-venous extracorporeal membrane oxygenation in pulmonary arterial hypertension - Bridging to recovery. Respir Med Res. 2021;80:100848.","journal-title":"Respir Med Res"},{"issue":"2","key":"3594_CR172","doi-asserted-by":"publisher","first-page":"e70088","DOI":"10.1002\/pul2.70088","volume":"15","author":"NA Kolaitis","year":"2025","unstructured":"Kolaitis NA, et al. Approach to lung transplantation in pulmonary arterial hypertension: a Delphi consensus on behalf of the transplant task force of the pulmonary vascular research institute. Pulm Circ. 2025;15(2):e70088.","journal-title":"Pulm Circ"},{"key":"3594_CR173","doi-asserted-by":"publisher","first-page":"e18743064359315","DOI":"10.2174\/0118743064359315250210080743","volume":"19","author":"R Masih","year":"2025","unstructured":"Masih R, et al. Revisiting acute decompensated right ventricle failure in pulmonary arterial hypertension. Open Respir Med J. 2025;19:e18743064359315.","journal-title":"Open Respir Med J"},{"key":"3594_CR174","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2023.11.012","volume":"365","author":"H Boucetta","year":"2024","unstructured":"Boucetta H, et al. Pulmonary arterial hypertension nanotherapeutics: new pharmacological targets and drug delivery strategies. J Control Release. 2024;365:236\u201358.","journal-title":"J Control Release"},{"issue":"11","key":"3594_CR175","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/resp.13552","volume":"24","author":"RL Harper","year":"2019","unstructured":"Harper RL, et al. BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo. Respirology. 2019;24(11):1095\u2013103.","journal-title":"Respirology"},{"issue":"12","key":"3594_CR176","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","volume":"27","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, et al. Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL. Gene Ther. 2020;27(12):579\u201390.","journal-title":"Gene Ther"},{"issue":"1","key":"3594_CR177","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-023-02487-2","volume":"24","author":"MG Katz","year":"2023","unstructured":"Katz MG, et al. Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction. Respir Res. 2023;24(1):197.","journal-title":"Respir Res"},{"issue":"5","key":"3594_CR178","doi-asserted-by":"publisher","first-page":"L1182","DOI":"10.1152\/ajplung.00020.2006","volume":"292","author":"AM Reynolds","year":"2007","unstructured":"Reynolds AM, et al. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1182\u201392.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"16","key":"3594_CR179","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1161\/CIRCULATIONAHA.124.070693","volume":"151","author":"SE Lemay","year":"2025","unstructured":"Lemay SE, et al. Exploring integrin \u03b15\u03b21 as a potential therapeutic target for pulmonary arterial hypertension: insights from comprehensive multicenter preclinical studies. Circulation. 2025;151(16):1162\u201383.","journal-title":"Circulation"},{"key":"3594_CR180","doi-asserted-by":"crossref","unstructured":"Rai N, et al. Genetic delivery and gene therapy in pulmonary hypertension. Int J Mol Sci, 2021;22(3).","DOI":"10.3390\/ijms22031179"},{"issue":"5","key":"3594_CR181","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.113.001585","volume":"128","author":"L Hadri","year":"2013","unstructured":"Hadri L, et al. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation. 2013;128(5):512\u201323.","journal-title":"Circulation"},{"key":"3594_CR182","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.copbio.2021.12.009","volume":"74","author":"JM Escandell","year":"2022","unstructured":"Escandell JM, et al. Leveraging rAAV bioprocess understanding and next generation bioanalytics development. Curr Opin Biotechnol. 2022;74:271\u20137.","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"3594_CR183","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1161\/CIRCULATIONAHA.120.047978","volume":"144","author":"M Bisserier","year":"2021","unstructured":"Bisserier M, et al. Regulation of the methylation and expression levels of the BMPR2 gene by SIN3a as a novel therapeutic mechanism in pulmonary arterial hypertension. Circulation. 2021;144(1):52\u201373.","journal-title":"Circulation"},{"key":"3594_CR184","doi-asserted-by":"crossref","unstructured":"Iglesias CF, Jr., et al. rAAV manufacturing: the challenges of soft sensing during upstream processing. Bioengineering (Basel). 2023;10(2):15-26.","DOI":"10.3390\/bioengineering10020229"},{"issue":"4","key":"3594_CR185","doi-asserted-by":"publisher","first-page":"204589401879973","DOI":"10.1177\/2045894018799738","volume":"8","author":"S Watanabe","year":"2018","unstructured":"Watanabe S, et al. Safety and long-term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension. Pulm Circ. 2018;8(4):2045894018799738.","journal-title":"Pulm Circ"},{"issue":"2","key":"3594_CR186","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"CS Lee","year":"2017","unstructured":"Lee CS, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4(2):43\u201363.","journal-title":"Genes Dis"},{"key":"3594_CR187","doi-asserted-by":"crossref","unstructured":"Park JS, et al. Fundamental and targeted approaches in pulmonary arterial hypertension treatment. Pharmaceutics, 2025;17(2)","DOI":"10.3390\/pharmaceutics17020224"},{"issue":"2","key":"3594_CR188","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4070\/kcj.2021.0191","volume":"52","author":"S Oh","year":"2022","unstructured":"Oh S, et al. Stem cell and exosome therapy in pulmonary hypertension. Korean Circ J. 2022;52(2):110\u201322.","journal-title":"Korean Circ J"},{"issue":"6","key":"3594_CR189","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.healun.2022.02.020","volume":"41","author":"QW Sun","year":"2022","unstructured":"Sun QW, Sun Z. Stem cell therapy for pulmonary arterial hypertension: an update. J Heart Lung Transplant. 2022;41(6):692\u2013703.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"3594_CR190","doi-asserted-by":"publisher","first-page":"204589321875597","DOI":"10.1177\/2045893218755979","volume":"8","author":"F Loisel","year":"2018","unstructured":"Loisel F, et al. Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy? Pulm Circ. 2018;8(2):2045893218755979.","journal-title":"Pulm Circ"},{"issue":"1","key":"3594_CR191","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/ATVBAHA.120.315052","volume":"41","author":"X Pu","year":"2021","unstructured":"Pu X, et al. Stem\/progenitor cells and pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2021;41(1):167\u201378.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"3594_CR192","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41440-021-00660-y","volume":"44","author":"GB Corssac","year":"2021","unstructured":"Corssac GB, et al. Pulmonary arterial hypertension induces the release of circulating extracellular vesicles with oxidative content and alters redox and mitochondrial homeostasis in the brains of rats. Hypertens Res. 2021;44(8):918\u201331.","journal-title":"Hypertens Res"},{"key":"3594_CR193","doi-asserted-by":"publisher","first-page":"1090909","DOI":"10.3389\/fcvm.2023.1090909","volume":"10","author":"Y Ren","year":"2023","unstructured":"Ren Y, Zhang H. Emerging role of exosomes in vascular diseases. Front Cardiovasc Med. 2023;10:1090909.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"3594_CR194","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/cvr\/cvad185","volume":"120","author":"PL Chi","year":"2024","unstructured":"Chi PL, et al. Induced pluripotent stem cell-derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1\u03b1 and Runx2. Cardiovasc Res. 2024;120(2):203\u201314.","journal-title":"Cardiovasc Res"},{"key":"3594_CR195","doi-asserted-by":"publisher","first-page":"123438","DOI":"10.1016\/j.biomaterials.2025.123438","volume":"323","author":"J Kim","year":"2025","unstructured":"Kim J, et al. Targeted delivery of apelin using a novel extracellular vesicle platform for pulmonary arterial hypertension treatment. Biomaterials. 2025;323:123438.","journal-title":"Biomaterials"},{"issue":"6","key":"3594_CR196","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/14728222.2025.2507034","volume":"29","author":"CV Flores","year":"2025","unstructured":"Flores CV, Chan SY. Therapeutic targets for pulmonary arterial hypertension: insights into the emerging landscape. Expert Opin Ther Targets. 2025;29(6):327\u201343.","journal-title":"Expert Opin Ther Targets"},{"issue":"3 Suppl","key":"3594_CR197","first-page":"S35","volume":"27","author":"DJ Levine","year":"2021","unstructured":"Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Manag Care. 2021;27(3 Suppl):S35-s41.","journal-title":"Am J Manag Care"},{"key":"3594_CR198","doi-asserted-by":"publisher","first-page":"107520","DOI":"10.1016\/j.vph.2025.107520","volume":"160","author":"M Abdulelah","year":"2025","unstructured":"Abdulelah M, et al. Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. Vascul Pharmacol. 2025;160:107520.","journal-title":"Vascul Pharmacol"},{"key":"3594_CR199","doi-asserted-by":"publisher","first-page":"795765","DOI":"10.3389\/fcvm.2021.795765","volume":"8","author":"T Shu","year":"2021","unstructured":"Shu T, et al. Multidisciplinary team managements and clinical outcomes in patients with pulmonary arterial hypertension during the perinatal period. Front Cardiovasc Med. 2021;8:795765.","journal-title":"Front Cardiovasc Med"},{"key":"3594_CR200","doi-asserted-by":"crossref","unstructured":"Coirier V, et al. Impact of three different algorithms for the screening of SSc-PAH and comparison with the decisions of a multidisciplinary team. Diagnostics (Basel). 2021;11(10):2.","DOI":"10.3390\/diagnostics11101738"},{"issue":"2","key":"3594_CR201","doi-asserted-by":"publisher","first-page":"2290923","DOI":"10.1080\/14767058.2023.2290923","volume":"36","author":"Q Dai","year":"2023","unstructured":"Dai Q, et al. Evaluation of maternal-fetal outcomes in pregnancy complicated with severe pulmonary hypertension and its influencing factors: a single-center retrospective study in China. J Matern Fetal Neonatal Med. 2023;36(2):2290923.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"4","key":"3594_CR202","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.resinv.2021.03.011","volume":"59","author":"B Tatius","year":"2021","unstructured":"Tatius B, et al. Significance of BMPR2 mutations in pulmonary arterial hypertension. Respir Investig. 2021;59(4):397\u2013407.","journal-title":"Respir Investig"},{"issue":"1","key":"3594_CR203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","volume":"10","author":"A Mocumbi","year":"2024","unstructured":"Mocumbi A, et al. Pulmonary hypertension. Nat Rev Dis Primers. 2024;10(1):1.","journal-title":"Nat Rev Dis Primers"},{"key":"3594_CR204","doi-asserted-by":"crossref","unstructured":"Sitbon O, et al. Drugs targeting novel pathways in pulmonary arterial hypertension. Eur Respir J. 2025;66(2):4.","DOI":"10.1183\/13993003.01830-2024"},{"issue":"1","key":"3594_CR205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2024.09.021","volume":"44","author":"TM Cascino","year":"2025","unstructured":"Cascino TM, et al. A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension. J Heart Lung Transplant. 2025;44(1):1\u201310.","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"3594_CR206","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s13770-022-00469-x","volume":"19","author":"L Ahmed","year":"2022","unstructured":"Ahmed L, Al-Massri K. New approaches for enhancement of the efficacy of mesenchymal stem cell-derived exosomes in cardiovascular diseases. Tissue Eng Regen Med. 2022;19(6):1129\u201346.","journal-title":"Tissue Eng Regen Med"},{"key":"3594_CR207","doi-asserted-by":"publisher","first-page":"1283233","DOI":"10.3389\/fendo.2023.1283233","volume":"14","author":"TM Zanotto","year":"2023","unstructured":"Zanotto TM, Gon\u00e7alves A, Saad MJA. Pulmonary hypertension and insulin resistance: a mechanistic overview. Front Endocrinol (Lausanne). 2023;14:1283233.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03594-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03594-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03594-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:03:23Z","timestamp":1780286603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03594-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":207,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3594"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03594-6","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}